- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharmaceuticals Inc stock price live, this page displays NASDAQ MIRM stock exchange data. View the MIRM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mirum Pharmaceuticals Inc real time stock price chart below.
What Is the Mirum Pharmaceuticals Inc Stock Price Today?
The Mirum Pharmaceuticals Inc stock price today is 52.02.
What Is the Stock Symbol for Mirum Pharmaceuticals Inc?
The stock symbol for Mirum Pharmaceuticals Inc is ""MIRM.""
What Stock Exchange Does Mirum Pharmaceuticals Inc Trade On?
Mirum Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Mirum Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Mirum Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MIRM quote. (ISIN: US6047491013)
What Is the Mirum Pharmaceuticals Inc Stock Price Today?
The Mirum Pharmaceuticals Inc stock price today is 52.02.
What Is the Stock Symbol for Mirum Pharmaceuticals Inc?
The stock symbol for Mirum Pharmaceuticals Inc is ""MIRM.""
What Stock Exchange Does Mirum Pharmaceuticals Inc Trade On?
Mirum Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Mirum Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Mirum Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MIRM quote. (ISIN: US6047491013)
52.02
+0.34(+0.66%)
Closed·
After Hours
52.020.00(0.00%)
·
Fair Value
An estimate of a Mirum Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51.33
52.74
52 wk Range
36.20
54.78
MIRM Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
MIRM is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Mirum Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
51.3352.74
52 wk Range
36.2054.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MIRM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Mirum Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
68.70
Upside
+32.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Mirum Pharmaceuticals Inc Company Profile
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals Inc SWOT Analysis
Rare Disease Pionee | Mirum Pharmaceuticals secures FDA approval for Ctexli, the first treatment for cerebrotendinous xanthomatosis in the US, bolstering its rare liver disease portfolio |
Financial Momentum | Q4 2024 revenues hit $99 million, contributing to full-year revenue of $336 million, an 81% year-over-year growth, with 2025 guidance set at $420-$435 million |
Pipeline Potential | Explore Mirum's promising pipeline, including volixibat for PSC and PBC, and MRM3379 for Fragile X Syndrome, representing billion-dollar market opportunities |
Market Valuation | Analysts maintain a bullish stance with a consensus recommendation of 1.4, and a price target of $74, reflecting confidence in Mirum's growth trajectory |
Mirum Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue of $111.6M beat forecasts by $13.58M; EPS of -0.3 slightly better than expected
- Full-year revenue guidance raised to $435-$450M; stock rose 3.32% in aftermarket trading to $42.59
- 61% YoY revenue growth driven by strong product demand and international expansion
- R&D expenses at $46M including $7M in milestone payments; cash and investments at $298.6M
- Enrollment for VISTA study expected to complete by Q3 2025; focus on expanding rare disease pipeline
Last Updated: 07/05/2025, 22:16
Read Full TranscriptCompare MIRM to Peers and Sector
Metrics to compare | MIRM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMIRMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.3x | −1.1x | −0.5x | |
PEG Ratio | −0.59 | −0.06 | 0.00 | |
Price/Book | 11.0x | 2.3x | 2.6x | |
Price / LTM Sales | 6.8x | 10.1x | 3.3x | |
Upside (Analyst Target) | 39.4% | 297.7% | 45.1% | |
Fair Value Upside | Unlock | 27.1% | 7.4% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 68.70
(+32.06% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
-0.30 / -0.31
Revenue / Forecast
111.60M / 98.02M
People Also Watch
FAQ
What Stock Exchange Does Mirum Pharmaceuticals Trade On?
Mirum Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Mirum Pharmaceuticals?
The stock symbol for Mirum Pharmaceuticals is "MIRM."
What Is the Mirum Pharmaceuticals Market Cap?
As of today, Mirum Pharmaceuticals market cap is 2.58B.
What Is Mirum Pharmaceuticals's Earnings Per Share (TTM)?
The Mirum Pharmaceuticals EPS (TTM) is -1.61.
When Is the Next Mirum Pharmaceuticals Earnings Date?
Mirum Pharmaceuticals will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is MIRM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Mirum Pharmaceuticals Stock Split?
Mirum Pharmaceuticals has split 0 times.
How Many Employees Does Mirum Pharmaceuticals Have?
Mirum Pharmaceuticals has 334 employees.
What is the current trading status of Mirum Pharmaceuticals (MIRM)?
As of 04 Aug 2025, Mirum Pharmaceuticals (MIRM) is trading at a price of 52.02, with a previous close of 52.02. The stock has fluctuated within a day range of 51.33 to 52.74, while its 52-week range spans from 36.20 to 54.78.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.